Linked Life Data

14734759

Source:http://linkedlifedata.com/resource/pubmed/id/14734759

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-1-21
pubmed:abstractText
Possible bioterrorism with smallpox has led to the resumption of smallpox (vaccinia virus) immunization. One complication, eczema vaccinatum, occurs primarily in patients with atopic dermatitis (AD). Skin lesions of patients with AD, but not psoriasis, is deficient in the cathelicidin antimicrobial peptide (LL-37) and human beta-defensin-2 (HBD-2). We hypothesized that this defect may explain the susceptibility of patients with AD to eczema vaccinatum. The Wyeth vaccine strain of vaccinia virus was incubated with varying concentrations of human (LL-37) and murine (CRAMP) cathelicidins, human alpha-defensin (HBD-1, HBD-2), and a control peptide. Outcomes included quantification of viral PFU, vaccinia viral gene expression by quantitative real-time RT-PCR, and changes in virion structure by transmission electron microscopy. CRAMP knockout mice and control animals were inoculated by skin pricks with 2 x 10(5) PFU of vaccinia and examined daily for pox development. Physiologic amounts of human and murine cathelicidins (10-50 micro M), but not human defensins, which had antibacterial activity, resulted in the in vitro reduction of vaccinia viral plaque formation (p < 0.0001), vaccinia mRNA expression (p < 0.001), and alteration of vaccinia virion structure. In vivo vaccinia pox formation occurred in four of six CRAMP knockout animals and in only one of 15 control mice (p < 0.01). These data support a role for cathelicidins in the inhibition of orthopox virus (vaccinia) replication both in vitro and in vivo. Susceptibility of patients with AD to eczema vaccinatum may be due to a deficiency of cathelicidin.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
172
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1763-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:14734759-Amino Acid Sequence, pubmed-meshheading:14734759-Animals, pubmed-meshheading:14734759-Antimicrobial Cationic Peptides, pubmed-meshheading:14734759-Cathelicidins, pubmed-meshheading:14734759-Drug Resistance, Microbial, pubmed-meshheading:14734759-Humans, pubmed-meshheading:14734759-Kaposi Varicelliform Eruption, pubmed-meshheading:14734759-Keratins, pubmed-meshheading:14734759-Mice, pubmed-meshheading:14734759-Mice, Inbred BALB C, pubmed-meshheading:14734759-Mice, Inbred C57BL, pubmed-meshheading:14734759-Mice, Knockout, pubmed-meshheading:14734759-Microbial Sensitivity Tests, pubmed-meshheading:14734759-Molecular Sequence Data, pubmed-meshheading:14734759-Polymerase Chain Reaction, pubmed-meshheading:14734759-Proteins, pubmed-meshheading:14734759-RNA, Viral, pubmed-meshheading:14734759-Vaccinia, pubmed-meshheading:14734759-Vaccinia virus, pubmed-meshheading:14734759-Virus Replication
pubmed:year
2004
pubmed:articleTitle
Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum.
pubmed:affiliation
Division of Allergy and Immunology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't